Europe DPP-4 Inhibitors Industry

Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Analysis

The Europe Dipeptide Peptidase 4 Inhibitors Market size is estimated at USD 1.84 billion in 2025, and is expected to reach USD 2.10 billion by 2030, at a CAGR of 2.73% during the forecast period (2025-2030).

Diabetes poses a significant health challenge on a global scale, and Europe is no different. As the number of diabetes cases continues to rise, the need for efficient treatments is more pressing than ever. Within the wide range of medications offered, Dipeptidyl Peptidase 4 (DPP-4) inhibitors have become a favored option for diabetes management, especially in Europe.

DPP-4 inhibitors are a class of oral medications used in the management of type 2 diabetes. They work by inhibiting the enzyme dipeptidyl peptidase 4, which increases the concentration of incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones help regulate blood sugar levels by stimulating insulin secretion and inhibiting glucagon release from the pancreas, thereby reducing blood glucose levels.

DPP-4 inhibitors are favored by healthcare professionals and patients due to their efficacy in lowering blood glucose levels without causing significant hypoglycemia (low blood sugar). They are also generally well-tolerated and have a low risk of weight gain, making them suitable for a wide range of patients, including those with comorbidities.

As Europe grapples with the challenges posed by the diabetes epidemic, DPP-4 inhibitors have emerged as valuable tools in the management of this chronic condition. Their efficacy, safety, oral administration, and potential cardiovascular benefits make them a preferred choice for healthcare providers and patients alike. Moving forward, addressing the underlying causes of diabetes and promoting preventive measures will be crucial in mitigating the burden of this disease on individuals and healthcare systems across Europe.

Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Trends

Increasing diabetes prevalence

The European region witnessed an alarming increase in the prevalence of diabetes in recent years. Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as oral anti-diabetic medication or ingestion of additional carbohydrates by monitoring their blood glucose levels. The rate of newly diagnosed Type 1 and Type 2 diabetes cases is seen to increase, mainly due to obesity, unhealthy diet, and physical inactivity. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure are indications of the increasing usage of diabetic drugs.

Dipeptidyl peptidase 4 (DPP-4) inhibitors are effective in treating type 2 diabetes, as they maintain blood glucose levels through the degradation of incretin peptides, glucagon-like peptide 1 (GLP-1), and glucose-dependent insulinotropic polypeptide. Oral Anti-Diabetic Drugs are available internationally and are recommended for use when treatment escalation for type 2 diabetes is required along with lifestyle management.

They are typically the first medications used in treating type 2 diabetes due to their wide range of efficacy, safety, and mechanisms of action. They help diabetes patients control their condition and lower the risk of diabetes complications. These agents present the advantages of easier management and lower cost, so they became an attractive alternative to insulin with better acceptance, which enhances adherence to the treatment.

The government and the companies are working towards better diabetes management. For instance, in the United Kingdom, the National Service Framework (NSF) program is improving services by setting national standards to improve service quality and tackle variations in care. The Association of British HealthTech Industries (ABHI) launched a diabetes section, enabling diabetes technology companies to work together in the first forum of its kind.

Owing to the rising rate of obesity, growing genetic factors for type-2 diabetes, the increasing prevalence, and the factors above, the market will likely continue to grow.

Germany held the highest market share in the European Dipeptide Peptidase 4 (DPP-4) Inhibitors Market in the current year

Diabetes is a significant health problem and one of the tremendous challenges for healthcare systems all over Germany. The prevalence of known type 1 & 2 diabetes in the German adult population is very high, along with many patients not yet diagnosed with the disease. Due to an aging population and unhealthy lifestyle, the prevalence of type 2 diabetes is expected to increase steadily over the next few years. High-quality care, including adequate monitoring, control of risk factors, and active self-management, are the key factors for preventing complications in German patients with type 2 diabetes.

The disease's growing incidence, prevalence, and progressive nature encouraged the development of new drugs to provide additional treatment options for diabetic patients. Non-insulin treatments, used as first-line therapies for patients with type 2 diabetes, currently capture more than half the sales in the anti-diabetic market. Over the past decade, two important classes entered this market: dipeptidyl peptidase-4 inhibitors (DPP-4) and sodium-glucose cotransporter-2 inhibitors (SGLT-2).

These agents work in various ways to reduce blood sugar levels in people with type 2 diabetes. Some stimulate insulin secretion by the pancreas, and others improve the responsiveness of cells to insulin or prevent glucose production by the liver. Others slow the absorption of glucose after meals. Also, the use of oral anti-diabetes drugs is rising because new-generation oral drugs, such as DPP-4 and SGLT-2, reduce the rate of CV risk in diabetes patients.

According to the German Diabetes Centre (DDZ), about 8.5 million people in Germany are affected by diabetes. The number of people with type 2 diabetes in Germany will continue to increase over the next twenty years. German law requires public plans to cap out-of-pocket health care costs and to cover all medically necessary treatment, including insulin.

Germany is one of the developed countries with advanced healthcare facilities. Moreover, reimbursement and pricing policies are highly regulated, which drives the market. The roll-out of many new products, increasing international research collaborations in technology advancement, and increasing awareness about diabetes among the people are some market opportunities for the players in the German market.

Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Overview

The European Dipeptide Peptidase 4 (DPP-4) Inhibitors Market is consolidated, with a few major manufacturers like Eli Lilly, AstraZeneca, Merck, Boehringer Ingelheim, Novartis, etc., gaining presence in major countries. At the same time, the remaining market comprises other local or region-specific manufacturers.

Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Leaders

Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Market News

• March 2024: Daiichi Sankyo made marketing alliance agreement with Mitsubishi Tanabe Pharma Corp for its DPP-4 inhibitor tablets, under the brand name Tenelia, will expire in September. The marketing deal for its SGLT2 inhibitor or Canaglu tablets will also expire that month.
• July 2022: European Commission released the Commission Implementing Decision granting marketing authorization under Regulation (EC) No 726/2004 of the European Parliament and the Council for "Sitagliptin/Metformin hydrochloride Accord - sitagliptin/metformin hydrochloride."